Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has provided an update.
Imricor Medical Systems, Inc. reported significant advancements in its operations and clinical trials in the first quarter of 2025. The company achieved key regulatory milestones, including the submission of its second Premarket Approval module to the US FDA and receiving CE Mark approval for its second-generation Vision-MR Ablation Catheter. A landmark event was the first-in-man ventricular ablation guided by real-time iCMR at Amsterdam University Medical Centre, marking a global first in the treatment of complex cardiac arrhythmia. The company also expanded its commercial team in Europe and the US, and reported a substantial increase in consumables revenue, although trial procedures remain non-revenue generating. Financially, Imricor raised A$70 million and maintained a strong cash balance, positioning itself for future growth.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. operates in the medical device industry, focusing on developing MRI-compatible products for cardiac ablation procedures. The company is known for its innovative iCMR (interventional cardiac magnetic resonance) technology, which enables real-time MRI-guided interventions, aiming to improve the precision and outcomes of cardiac arrhythmia treatments.
YTD Price Performance: 8.09%
Average Trading Volume: 375,365
For a thorough assessment of IMR stock, go to TipRanks’ Stock Analysis page.